David Bond, MD, Discusses the LION Study in R/R MCL
By Leah Sherwood, David Bond, MD - Last Updated: February 1, 2023David Bond, MD, of the Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital, discusses a study based on data from the LION Prospective Observational Registry. The study, which Dr. Bond and colleagues presented during the 2022 American Society of Hematology Annual Meeting, showed that with the availability of novel therapies, patients who experienced their first and second relapse of mantle cell lymphoma had favorable overall survival.
Advertisement
Post Tags:ASH22
Advertisement
Related Posts
Machine learning may aid point-of-care clinical decision-making for NHL patients receiving CAR T-cell therapy.
Martin Dreyling, MD, discusses the TRIANGLE study and the shifting roles of autologous HSCT and chemotherapy in MCL.
Melody Smith, MD, MS, shares data on burnout in hematologist oncologists, why it occurs, and how to prevent it.
A panel moderated by Neil Love, MD, explored clinical data to assess these treatment approaches for the various types of NHL.
Clinical evaluations of this bispecific antibody as monotherapy or in polytherapy for B-cell non-Hodgkin lymphomas continue.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.